Boehringer Just Bought Six Options on China's Oncology Pipeline
Sino Biopharmaceutical optioned six preclinical oncology programs to Boehringer Ingelheim for $358 million upfront and up to $7 billion in milestones, with Phase I results deciding which options get exercised.












